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Abstract 
The gene encoding for the methionyl aminopeptidase from the hyperthermophilic archaeon Pyrococcus 
furiosus (PfMetAP-II; EC 3.4.11.18) has been inserted into a pET 27b(+) vector and overexpressed in Escherichia 
coli. The new expression system resulted in a 5-fold increase in purified enzyme obtained from a 5 L fermentor 
growth. The as-purified PfMetAP-II enzyme, to which no exogenous metal ions or EDTA was added, was found to 
have 1.2 equiv of zinc and 0.1 equiv of iron present by ICP-AES analysis. This enzyme had a specific activity of 5 
units/mg, a 60-fold decrease from the fully loaded Fe(II) enzymes. When an additional 2 equiv of Zn(II) was 
added to the as-purified PfMetAP-II, no activity could be detected. The combination of these data with 
previously reported whole cell studies on EcMetAP-I further supports the suggestion that the in vivo metal ion 
for all MetAP's is Fe(II). Both Co(II)- and Fe(II)-loaded PfMetAP-II showed similar substrate specificities 
to EcMetAP-I. Substrate binding was largely affected by the amino acid in the P1 position and the length of the 
polypeptide. The substrates MSSHRWDW and MP-p-NA showed the smallest Km values while the substrates 
MGMM and MP-p-NA provided the highest turnover. The catalytic efficiency (kcat/Km) of PfMetAP-II for MP-p-NA 
at 30 °C was 799 500 and 340 930 M-1 s-1 for Co(II)- and Fe(II)-loaded PfMetAP-II, respectively. Maximum 
catalytic activity was obtained with 1 equiv of Co(II) or Fe(II), and the dissociation constants (Kd) for the first 
metal binding site were found to be 50 ± 15 and 20 ± 15 nM for Co(II)- and Fe(II)-substituted PfMetAP-II, 
respectively. Electronic absorption spectral titration of a 1 mM sample of apo-PfMetAP-II with Co(II) provided a 
dissociation constant of 0.35 ± 0.02 mM for the second metal binding site, a 17500-fold increase compared to 
the first metal binding site. The electronic absorption data also indicated that both Co(II) ions reside in a 
pentacoordinate geometry. PfMetAP-II shows unique thermostability and the optimal temperature for substrate 
turnover was found to be ∼85 °C at pH 7.5 in 25 mM Hepes and 150 mM KCl buffer. The hydrolysis of MGMM 
was measured in triplicate between 25 and 85 °C at eight substrate concentrations ranging from 2 to 20 mM. 
Both specific activity and Km values increased with increasing temperature. An Arrhenius plot was constructed 
from the kcat values and was found to be linear over the temperature range 25−85 °C, indicating that the rate-
limiting step in PfMetAP-II peptide hydrolysis does not change as a function of temperature. Co(II)- and Fe(II)-
loaded PfMetAP-II have similar activation energies (13.3 and 19.4 kJ/mol, respectively). The thermodynamic 
parameters calculated at 25 °C are as follows:  ΔG⧧ = 46.23 kJ/mol, ΔH⧧ = 10.79 kJ/mol, and ΔS⧧ = −119.72 J·mol-
1·K-1 for Co(II)-loaded PfMetAP; ΔG⧧ = 46.44 kJ/mol, ΔH⧧ = 16.94 kJ/mol, and ΔS⧧ = −99.67 J·mol-1·K-1 for Fe(II)-
loaded PfMetAP. Interestingly, at higher temperatures (>50 °C), Fe(II)-loaded PfMetAP-II is more active (1.4-fold 
at 85 °C) than Co(II)-loaded PfMetAP-II. 
 
Methionyl aminopeptidases (MetAP's)1 represent a unique class of proteases that are capable of the hydrolytic 
removal of N-terminal methionine residues from nascent polypeptide chains (1−4). In prokaryotes, 
mitochondria, and chloroplasts the initiator residue is an N-formyl methionine group. The N-formyl group is 
removed from proteins in prokaryotes and eukaryotic organelles by a deformylase, leaving a methionine residue 
at the amino terminus (2). Many mature proteins do not retain an N-terminal methionine residue since they 
require modifications and/or processing during and after translation (5). Examples include the removal of signal 
sequences, proteolytic cleavage to generate shorter peptides, and the covalent attachment of residues and 
blocking groups (e.g., acetyl and myristoyl groups). The structure of the mature N-terminus plays a critical role in 
N-directed degradation pathways and in targeting cellular membranes (1−4). The physiological importance of 
MetAP activity is underscored by the fact that deletion of MetAP genes in Escherichia coli, Salmonella 
typhimurium, and Saccharomyces cerevisiae is lethal to the cell (6−8). Moreover, MetAP's have recently been 
identified as the molecular target for the epoxide-containing antiangiogenesis agents TNP-470 and fumagillin, 
one of which is in phase III clinical trials (9−13). Therefore, MetAP's represent an important target for the 
development of novel anticancer, antibacterial, and/or antifungal agents. 
MetAP's are organized into two classes (type I and type II) on the basis of the absence or presence of a 62 amino 
acid sequence inserted near the C-terminus. The function of this insert has yet to be established. The MetAP's 
from E. coli (type I), Homo sapiens (type II), and Pyrococcus furiosus (type II) have been crystallographically 
characterized (13−16). All three have been shown to have identical catalytic domains that contain a bis(μ-
carboxylato)(μ-aquo/hydroxo)dicobalt core with an additional carboxylate residue at each metal site and a 
single histidine residue bound to one of the two metal ions (13−16). Since all of the catalytic domain residues are 
completely conserved in both type I and type II MetAP's, all MetAP's should bind divalent metal ions similarly. 
With this in mind, it was recently suggested that the in vivo metal ion for the type I MetAP from E. 
coli (EcMetAP-I) is Fe(II) on the basis of whole cell metal analyses, activity measurements, and substrate binding 
constants (17, 18). In addition, the observed catalytic activity as a function of divalent metal ion and the metal 
binding constants for both Fe(II) and Co(II) EcMetAP-I led to the proposal that MetAP's function as mononuclear 
enzymes in vivo, which was recently corroborated by extended X-ray absorption fine structure (EXAFS) 
spectroscopy (17, 19). The high-affinity or catalytically relevant metal binding site was assigned as the histidine-
containing site. However, Yang et al. (20) more recently suggested that the type II MetAP from H. 
sapiens (HsMetAP-II) binds divalent metal ions differently from type I MetAP enzymes in that HsMetAP-II 
requires two Co(II) ions to be fully activated (20). 
To understand the reported differences in the divalent metal binding properties between type I and type II 
MetAP's, we have examined how the type II MetAP from P. furiosus (PfMetAP-II) binds divalent metal 
ions. PfMetAP-II is by far the most thermostable member of the MetAP family of enzymes, with an optimum 
catalytic activity around 85 °C with a half-life of approximately 4.5 h (21). PfMetAP-II and HsMetAP-II are 39% 
identical while PfMetAP-II and EcMetAP-I are 33% identical, suggesting that structural and mechanistic data 
obtained for PfMetAP-II will likely be similar to that determined for HsMetAP-II and EcMetAP-I. To further 
examine the structure and function of PfMetAP-II, a new expression system for the PfMetAP-II gene was 
developed that produces five times more enzyme than the previously reported overexpression system. We have 
also examined the substrate specificity, metal binding properties, and temperature dependence of the catalytic 
activity of PfMetAP-II in the presence of either Co(II) or Fe(II). Comparison of the data presented herein with 
other MetAP's suggests that both type I and type II MetAP's bind divalent metal ions in an identical fashion and 
are likely mononuclear Fe(II)-dependent metalloproteases. 
Materials and Methods 
Purification of Recombinant PfMetAP-II.  
PfMetAP-II was purified similarly to that previously reported with minor modifications (21). Briefly, frozen cells 
(∼35 g) were thawed and suspended in 100 mL of 20 mM Tris-HCl buffer, pH 7.5. To this solution were added 
0.5 mL of 100 mM PMSF, 4.5 mg of lysozyme, 4.5 mg of DNase I, and 10 μL of 1 M MgCl2. This solution was 
stirred for 30 min at 25 °C followed by cooling to 4 °C for 1 h. This cell solution was sonicated in 50 mL aliquots 
for three 1 min intervals with ∼2 min intervals on ice. The mixture was then heated for 10 min at 100 °C. After 
centrifugation at 18000 rpm for 45 min, the supernatant was concentrated by ultrafiltration using an Amicon YM 
10 membrane and dialyzed against 20 mM phosphate buffer, pH 8.0, overnight, with two buffer changes. The 
dialyzate was loaded onto a DEAE-Sepharose CL-6B column (Pharmacia, 2.5 × 16 cm) equilibrated with 20 mM 
phosphate buffer, pH 8.0. The protein was eluted at a flow rate of 1 mL/min with a linear gradient of 0−0.5 M 
KCl. The fractions containing PfMetAP-II were identified by SDS−PAGE, combined and concentrated to ∼20 mL, 
and then dialyzed against 10 mM phosphate buffer at pH 7.0 overnight. This dialyzate was loaded onto a CM-
Sepharose CL-6B column (Pharmacia, 1.5 × 12 cm) equilibrated with phosphate buffer at pH 7.0. A linear 
gradient of 0−0.5 M KCl was used to elute the protein. Fractions containing PfMetAP-II were concentrated to 
3−4 mL using a Centriprep-10 (Millipore Corp.) and then loaded onto a gel filtration column (Sephadex 75 Hi-
load prep-grade 16/60, Pharmacia) equilibrated with phosphate buffer at pH 7.0, containing 0.2 M KCl, at a flow 
rate of 0.3 mL/min. Purified PfMetAP-II exhibited a single band on a SDS−PAGE, providing a Mr of 32850. Protein 
concentrations were estimated from the absorbance at 280 nm using an extinction coefficient of 21650 M-1 cm-1. 
Metal-free PfMetAP-II was prepared by concentrating the as-purified PfMetAP-II to a volume of ∼5 mL, after 
which EDTA was added to a final concentration of 10 mM. The resulting protein solution was dialyzed against 25 
mM Hepes buffer (2 L, pH 7.5) containing 10 mM EDTA and 150 mM KCl at 4 °C for 2 days with two buffer 
changes per day. The protein solution was then dialyzed against chelexed (Chelex-100 Column) 25 mM Hepes 
buffer (2 L, pH 7.5) containing 150 mM KCl for 3 days against two buffer changes per day. The 
resulting PfMetAP-II was inactive and was found to contain no detectable metal ions via inductively coupled 
plasma atomic emission spectrometry (ICP-AES). This enzyme deemed “apo-PfMetAP-II” was stored at −80 °C. 
Metal Content Measurements.  
Enzyme samples for metal analysis were typically 30 μM. Apo-PfMetAP-II samples were incubated under 
anaerobic conditions with Co(II) or Fe(II) (CoCl2 or FeSO4, ≥99.999%; Strem Chemicals, Newburyport, MA) for 30 
min prior to exhaustive dialysis under anaerobic conditions against Chelex-treated buffer as previously reported 
(17, 18). Metal analyses were performed using ICP-AES. 
Enzymatic Assay of PfMetAP-II.  
All assays were performed under strict anaerobic conditions in an inert atmosphere glovebox (Coy) with a dry 
bath incubator to maintain the temperature. Catalytic activities were determined with an error of ±5%. Enzyme 
activity was determined in 25 mM Hepes buffer, pH 7.5, containing 150 mM KCl with different substrates 
(MGMM, MAS, and MSSHRWDW). The amount of product formation was determined by high-performance 
liquid chromatography (HPLC; Shimadzu LC-10A Class-VP5). Metal-substituted PfMetAP-II samples were 
prepared by adding 3 equiv of the appropriate divalent metal ion to a buffered solution of 10 μM apo-PfMetAP-
II, and the mixture was incubated at 30 °C for 30 min. A typical assay involved the addition of 4 μL of M(II)-
loaded PfMetAP-II to a 16 μL substrate−buffer mixture followed by incubation at 30 °C for 1 min. The reaction 
was quenched by the addition of 20 μL of 1% trifluoroacetic acid solution (TFA). The elution of the products was 
monitored at 215 nm following separation on a C8 HPLC column (Phenomenex, Luna; 5 μm, 4.6 × 25 cm). 
Gradient elution was used at 1.5 mL/min. For the substrates MAS and MGMM, solvent A was 0.1% TFA in water, 
and solvent B was 50% Nanopure water, 50% HPLC-grade acetonitrile, and 0.1% TFA. For MGMM the starting 
gradient was 95/5 (A/B), and after 2 min the concentration of solvent B was increased from 5% to 100% over 10 
min. The eluent mixture was held at 100% solvent B for an additional 2 min. Then the gradient was decreased to 
5% in one second and continued to run at 5% solvent B for 2 min. The product GMM eluted around 10.7 min, 
and the substrate MGMM was eluted at around 11.8 min. For substrate MAS, the starting gradient was 100/0 
(A/B). The gradient was increased from 0% to 5% solvent B within 2 min and then from 5% to 8% in 1 min; 
solvent B was increased from 8% to 50% in 5 min and then increased to 100% in the next 2 min. After running 
100% solvent B for 2 min, 100% solvent A was run for another 2 min. The product AS was eluted at 2.6 min, and 
the substrate MAS was eluted at about 8.6 min. For the octapeptide MSSHRWDW, 98% water, 2% acetonitrile, 
and 0.1% TFA were used as mobile phase A and 100% acetonitrile and 0.1% TFA as mobile phase B. The gradient 
was increased from 0% to 17% solvent B during the first 2 min and then increased to 27% over the next 16 min, 
followed by 100% solvent B for 2 min; 100% solvent A was added for another 5 min. The product SSHRWDW was 
eluted at about 15.5 min, and the substrate MSSHRWDW was eluted at about 16.5 min. Activity was determined 
on the basis of the amount of product (AS, GMM, or SSHRWDW) formed using a standard curve generated by 
running HPLC chromatograms of known concentrations of the dipeptide, tripeptide, and heptapeptide. 
The kinetic parameters V (velocity) and Km (Michaelis constant) were determined in triplicate. Enzyme activities 
are expressed as units per milligram, where one unit is defined as the amount of enzyme that releases 1 μmol of 
product at 30 °C in 1 min. The metal binding titration and temperature dependence reactions were carried out 
using the same conditions as determined for the kinetic constants. The hydrolysis of MP-p-NA was monitored 
spectrophotometrically at 405 nm on the basis of the increase in absorbance of p-NA (Δε405 value of p-
nitroaniline of 10600 M-1 cm-1) (18). The reaction mixture consisted of 5 μL of 10 μM enzyme solution, 3 μL of 2.0 
mM prolidase, and substrate solution in different concentrations to a final volume of 1000 μL. One unit was 
defined as the amount of enzyme that releases 1 μmol of p-NA at 25 °C in 1 min. 
Spectroscopic Measurements.  
Electronic absorption spectra were recorded on a Shimadzu UV-3101PC spectrophotometer. All apo-PfMetAP-II 
samples used in spectroscopic measurements were rigorously degassed prior to incubation with Co(II) or Fe(II) 
(CoCl2 or FeSO4, ≥99.999%; Strem Chemicals, Newburyport, MA) for ∼30 min at 25 °C. All Co(II)- and Fe(II)-
containing samples were handled in an anaerobic glovebox (95% N2/5% H2, ≤1 ppm of O2; Coy Laboratories). 
Electronic absorption spectra were normalized for the protein concentration and the absorption due to 
uncomplexed Co(II) (ε512 nm = 6.0 M-1 cm-1). 
Results 
Overexpression and Purification of PfMetAP-II.  
The original culture of E. coli strain JM109 carrying the plasmid containing the gene for PfMetAP-II showed low 
levels of expression that were insufficient for detailed kinetic and spectroscopic studies (21). To increase the 
yield of PfMetAP-II, the PfMetAP-II gene was cloned and placed into a pET 27b(+) expression vector. The original 
vector containing the PfMetAP-II gene was isolated using a Wizard Plus Miniprep DNA purification kit (Promega). 
The plasmid was used as the template for PCR (PCR Kit, Amersham Pharmacia Biotech Inc.) to engineer 
restriction sites for NdeI and SalI using primers synthesized by Operon Technologies. The primers used were the 
follows:  upper primer, 5‘-GTC TGG CAT ATG GAT ACT GAA AAA CTT-3‘ (NdeI restriction site underlined); lower 
primer, 5‘-GCT GAG GTC GAC TCA TTC TGT CGT CAC TAT-3‘ (SalI restriction site underlined). The PCR product of 
0.9 kbp was purified on and excised from an agarose gel using a Qiaex Gel Extraction Kit (Qiagen) (Figure 1). The 
gene was sequenced and was identical to that previously reported for PfMetAP-II. The PCR product was inserted 
into a pGEM-T easy cloning vector (Promega). Isolated plasmid was digested with the restriction enzymes NdeI 
and SalI and ligated into the pET 27b(+) expression vector that had been digested with NdeI and SalI (Novagen). 
This plasmid was transformed into BL21 E. coli cells. Transformants were again screened using restriction 
digests, and IPTG induced protein overexpression of E. coli BL21 cells grown in a shake flask for 12−14 h at 37 °C, 
containing 15 mg of kanamycin. Cells were grown in a 5 L fermentor at 37 °C with an air flow of 12 L/min to 
which 1 mM IPTG was added to induce protein expression at an OD600 of 1.0. The cells were allowed to grow for 
3 h to 28 °C and then harvested by centrifugation at 8000 rpm for 15 min at 4 °C. After overexpression and 
purification, the increase in protein production from a 5 L fermentor was 5-fold, allowing 100 mg of 
purified PfMetAP-II to be obtained from 5 L. 
 
Figure 1 Agarose gel of the PfMetAP-II gene after PCR. Lane 1 is the molecular weight marker, and lanes 2−5 are 
the 0.9 kbp gene encoding for PfMetAP-II. 
 
Analyses of the Metal Ion Content of PfMetAP-II.  
The metal content of purified PfMetAP-II, to which no supplemental metal ions or EDTA had been added 
throughout the cellular growth and purification process, contained 1.2 equiv of zinc and 0.1 equiv of iron. No 
cobalt was detected. The specific activity of this enzyme at 30 °C, pH 7.5, using MGMM as the substrate was 5.0 
units/mg, which is ∼60 times less active than either the Co(II)- or Fe(II)-loaded PfMetAP-II enzyme. 
The number of tightly bound divalent metal ions was determined for PfMetAP-II by ICP-AES analysis. PfMetAP-II 
samples (30 μM), to which 2−30 equiv of either Co(II) or Fe(II) was added, were dialyzed extensively for 3 h at 4 
°C against metal-free Hepes buffer. Upon ICP-AES analysis, 1.0 ± 0.1 equiv of cobalt or iron was tightly bound to 
the enzyme. These data suggest that only one Co(II) or one Fe(II) ion is tightly bound to PfMetAP-II while the 
second metal ion is labile on the time scale of the buffer exchange (3 h, 4 °C). In a separate experiment, 2 equiv 
of Co(II) or Fe(II) were added to apo-PfMetAP-II (30 μM), after which they were oxidized in air. The addition of 
hydrogen peroxide to the Co(II)-loaded PfMetAP-II enzyme resulted in a distinct color change from violet/pink to 
brown, indicative of the formation of low-spin octahedral Co(III). Moreover, no EPR spectrum could be detected, 
consistent with diamagnetic Co(III) ions. After extensive dialysis at 4 °C with metal-free Hepes buffer, 2 equiv of 
cobalt or iron were found associated with PfMetAP-II on the basis of ICP-AES analysis. These data suggest that 
Co(II) and Fe(II) are oxidized to Co(III) and Fe(III) forming [Co(III)Co(III)MetAP] and [Fe(III)Fe(III)(MetAP)] 
enzymes, both of which are inactive. 
Substrate and Metal Ion Dependence on the Specific Activity of PfMetAP-II.  
Kinetic constants and specific activities for both Co(II)- and Fe(II)-loaded PfMetAP-II were determined for the 
peptide substrates MAS, MGMM, MSSHRWDW, and MP-p-NA (Table 1). Activity assays were performed in 
triplicate for 8−15 concentrations for each substrate (MAS, 0−60 mM; MGMM, 0−12 mM; MSSHRWDW, 0−12 
mM; MP-p-NA, 0−1.2 mM). The product was quantified by HPLC or by monitoring the absorption at 405 nm 
for p-NA. The Km and Vmax values were obtained by nonlinear fitting of the data to the Michaelis−Menten 
equation. The kcat and specific activity values were calculated using a molecular weight of 32850 and a molar 
absorptivity at 280 nm of 21650 M-1 cm-1. The specific activities of PfMetAP-II at 30 °C varied markedly on the 
basis of the substrate used. For the weakly binding tripeptide substrate MAS (Km = 11.8 mM) the specific activity 
for Co(II)-loaded PfMetAP-II was 35 units/mg whereas the tetrapeptide MGMM (Km = 5.1 mM) exhibited a 
specific activity of 340 units/mg. These activities compare well with the only activity data reported to date 
for PfMetAP-II of 30 units/mg toward the pentapeptide MPAAG. Fe(II) also activates PfMetAP-II under anaerobic 
conditions. The trends in Km and specific activity for Fe(II)-loaded PfMetAP-II are similar to the Co(II)-loaded 
enzyme as well as the Fe(II)- and Co(II)-loaded EcMetAP-I. 
 
Figure 2 Plot of specific activity vs equivalents of added metal ion [(·) Co(II) and (▴) Fe(II)] to an 8.3 μM sample 
of PfMetAP-II (25 mM Hepes buffer, pH 7.5, 150 mM KCl). Inset:  Fits of the (·) Co(II) and (▴) Fe(II) activity data 
to eq 1. 
 
Table 1:  Kinetic Constants for Fe(II)- and Co(II)-Loaded PfMetAP-II for Various Substrates at 30 °C and pH 7.5 
metal kinetic constants MAS MGMM MSSHRWDW MP-p-NA 
Co(II) Km (mM) 11.8 ± 0.2 5.1 ± 0.3 2.0 ± 0.2 0.197 ± 0.015 
  kcat (s-1) 19 188 16 157 
  kcat/Km (M-1 s-1) 1610 36900 8000 799500 
  SA (units/mg) 35 ± 4 340 ± 8 29 ± 3 287 ± 6 
Fe(II) Km (mM) 9.2 ± 0.4 5.0 ± 0.6 1.3 ± 0.2 0.135 ± 0.02 
  kcat (s-1) 14 153 22 46 
  kcat/Km (M-1 s-1) 1520 30600 17200 340930 
  Vmax (nmol min-1) 16.8 ± 0.2 92 ± 9 6.7 ± 0.3 138 ± 4 
  SA (units/mg) 25 ± 2 280 ± 10 41 ± 2 84 ± 2 
 
Activity as a Function of Divalent Metal Ion Concentration.  
The extent of hydrolytic activity exhibited by PfMetAP-II was determined as a function of divalent metal ion 
concentration. Apo-PfMetAP-II (8.3 μM) was incubated with varying amounts of Co(II) or Fe(II), and the level of 
catalytic activity was determined (Figure 2). Upon the addition of Co(II) to PfMetAP-II under anaerobic 
conditions, the specific activity increased as a function of metal ion concentration up to 1 equiv of Co(II). Further 
additions of up to 5 equiv of Co(II) had no effect on the enzymatic activity. Interestingly, upon the addition of 
Co(II) to >83 μM (∼10 equivalents) the activity steadily decreased until ∼3.3 mM Co(II) had been added (400 
equiv), at which time the activity was ∼30% of the maximum activity (Figure 2). Further additions of up to 800 
equiv of Co(II) had no effect on the enzymatic activity. The decrease in activity could be due to the occupation of 
a second metal binding site or may be the result of chelation of the tetrapeptide substrate by excess divalent 
metal ions. Analogous behavior was also observed for Fe(II) (Figure 2). 
The activity titration data for Co(II) and Fe(II) binding to PfMetAP-II were fit to the equation (24): 
𝑟𝑟 = 𝑝𝑝𝑝𝑝𝑠𝑠/(𝐾𝐾𝑑𝑑 + 𝑝𝑝𝑠𝑠) (1) 
where p is the number of sites for which interaction with M(II) is governed by the intrinsic dissociation 
constant Kd and r is the binding function calculated by conversion of the fractional saturation (fa) using the 
equation: 
𝑟𝑟 = 𝑓𝑓𝑎𝑎𝑝𝑝 (2) 
CS, the free metal concentration, was calculated using the equation: 
𝑝𝑝𝑠𝑠 = 𝑝𝑝𝑇𝑇𝑇𝑇 − 𝑟𝑟𝑝𝑝𝐴𝐴 (3) 
where CTS and CA are the total and free molar concentrationsof metal and enzyme, respectively. A value for the 
dissociation constant (Kd) was obtained by fitting the data via an iterative process that allowed both Kd and p to 
vary (Figure 2, inset). The best fit obtained provided a p value of 1 and Kd values of 50 ± 15 and 20 ± 15 nM for 
Co(II)- and Fe(II)-substituted PfMetAP-II, respectively. 
Electronic Absorption Spectra of Co(II)-Bound PfMetAP-II.  
The electronic absorption spectrum of a 1 mM sample of PfMetAP-II with various amounts of Co(II) added was 
recorded under strict anaerobic conditions in 25 mM Hepes buffer, pH 7.5, and 150 mM KCl (Figure 3). The 
addition of one Co(II) ion to PfMetAP-II provided an electronic absorption spectrum with λmax values of 562 
(ε562 = 110 M-1 cm-1), 525 (ε525 = 72 M-1 cm-1), and 590 nm (ε590 = 93 M-1 cm-1). Further addition of Co(II) resulted 
in increases in absorption at 525 and 562 nm, consistent with the occupation of an additional metal binding site 
(Figure 3). The dissociation constant (Kd) for the second divalent metal binding site was obtained by fitting these 
data to eq 1 (Figure 4). The best fit obtained provided a p value of 1 and a Kd value of 0.35 ± 0.05 mM. 
 
Figure 3 Electronic absorption spectral titration of 1 mM PfMetAP-II (25 mM Hepes buffer, pH 7.5, 150 mM KCl) 
with Co(II) in 0.25 equiv increments. 
 
 
Figure 4 Plot of binding function, r, vs CS (the concentration of free metal ions in solution) for λ562 of a 1 
mM PfMetAP-II sample (25 mM Hepes buffer, pH 7.5, and 150 mM KCl).       
 
Temperature Dependence of the Hydrolysis of Met-Gly-Met-Met by PfMetAP-II. It was previously reported 
that PfMetAP-II is stable at 75 °C for 60 min within the pH range 4.5−10.5. We have confirmed the thermal 
stability of PfMetAP-II and have found that the optimal activity with MGMM as the substrate occurred at 85 °C 
in 25 mM Hepes, pH 7.5, and 150 mM KCl buffer. This provides us the unique opportunity to probe the 
thermodynamic properties of the PfMetAP-II catalyzed hydrolysis of N-terminal methionine residues. The 
hydrolysis of MGMM was measured in triplicate between 25 and 85 °C at eight substrate concentrations ranging 
from 2 to 20 mM. From these data, Km values were derived by fitting the experimental data to the 
Michaelis−Menten equation at each temperature studied (Figure 5B). The calculated specific activity values 
were plotted as a function of temperature between 25 and 85 °C (Figure 5A). The Km and specific activity values 
for MGMM hydrolysis catalyzed by Co(II)- and Fe(II)-loaded PfMetAP-II were found to increase with increasing 
temperature. PfMetAP-II was stable at 85 °C for approximately 30 min before any loss in the enzymatic activity 
was detected. However, any loss in activity was fully reversible as a function of Vmax for temperatures up to 70 
°C. These data are very unusual since most enzymes undergo some denaturation at temperatures above 50 °C, 
resulting in a decrease in Vmax (22). 
 
Figure 5 (A) Plot of specific activity (units/mg) of Co(II)- (·) and Fe(II)-loaded (▴) PfMetAP-II vs temperature 
between 23 and 85 °C. Each data point is the sum of three activity measurements at pH 7.5, 25 mM Hepes 
buffer and 150 mM KCl, at substrate concentrations ranging from 2 to 20 mM. (B) Km vs temperature (°C).      
  
In a simple rapid equilibrium Vmax/[E] = kp, the first-order rate constant. Since the enzyme concentration was not 
altered over the course of the experiment, an Arrhenius plot can be constructed by plotting ln kcat vs 1/T (Figure 
6). A linear plot was obtained, indicating that the rate-limiting step does not change as the temperature is 
increased (22). From the slope of the line the activation energy, Ea, for temperatures between 296 and 358 K 
was calculated to be 13.3 kJ/mol for Co(II)-loaded PfMetAP-II and 19.4 kJ/mol for Fe(II)-loaded enzyme. Since 
the slope of an Arrhenius plot is equal to −Ea1/R, where R = 8.3145 J·K-1·mol-1, other thermodynamic parameters 
were calculated by the following relations:  ΔG⧧ = −RT ln(kcath/kBT), ΔH⧧ = Ea − RT, and ΔS⧧ = (ΔH⧧ − ΔG⧧)/T, 
where kB, h, and R are the Boltzmann, Planck, and gas constants, respectively (Table 2). 
 
Figure 6 Arrhenius plot of ln kcat vs 1/T for Co(II)- (·) and Fe(II)-loaded (▴) PfMetAP-II. The solid and dashed lines 
are direct fits to the Arrhenius equation. 
 
Table 2:  Thermodynamic Parameters for the Hydrolysis of MGMM 
enzyme Ea (kJ/mol) ΔH⧧ (kJ/mol) ΔG⧧ (kJ/mol) ΔS⧧ (J·mol-1·K-1) 
Co(II)-PfMetAP 13.3 11 46 −119.7 
Fe(II)-PfMetAP 19.4 17 46 −99.7 
 
Discussion 
To effectively design small molecules that specifically target either type I or type II MetAP's and act as 
anticancer, antibacterial and/or antifungal agents, a knowledge of the variety and number of in vivo metal ions 
is required. Until recently, all MetAP's studied had been reported to require two Co(II) ions in a dinuclear active 
site (13−16). The conclusion that MetAP's are Co(II)-dependent enzymes was primarily arrived at from the 
reproducible observations that MetAP's show high activity in the presence of Co(II) when compared to the 
activity levels of other divalent metal ions (23). However, in all in vitro studies to date, Co(II) concentrations 
have been artificially increased to the millimolar range during purification. Moreover, several metalloproteases 
with active site ligands similar to those of MetAP's can substitute their native divalent metal ions with Co(II) in 
vitro, and in most cases, active and even hyperactive enzymes are obtained (24, 25). Because Co(II) is not 
abundant in nature and no biological systems require Co(II), except vitamin B12 where the cobalt ion resides in a 
very rigid corrin ring system (24), the suggestion that MetAP's are Co(II)-dependent hydrolases has been called 
into question (17, 18, 26). Walker and Bradshaw reported that the type I MetAP from S. cerevisiae is fully active 
with Zn(II) in the presence of millimolar concentrations of EDTA but that excess Zn(II) was inhibitory (26). More 
recently, EcMetAP-I was shown to be completely inactive in the presence of Zn(II) ions but is fully active with 
only 1 equiv of Co(II) or Fe(II) (18). Unlike Co(II), Fe(II) is very abundant in nature and has many biological roles 
(24). On the basis of these data it was suggested that Fe(II) is the physiologically relevant metal ion for MetAP's 
(18). However, a recent study on HsMetAP-II suggested that Co(II) is strictly required to activate this enzyme. 
Yang et al. (20) further suggested that type II MetAP's have different metal binding properties than type I 
MetAP's. Given the fact that the active site ligands in all MetAP's are strictly conserved (27) and the three X-ray 
crystal structures of both type I and type II MetAP's indicate that the active sites are superimposable (13−16), 
one would expect the metal binding properties of all MetAP's to be identical. Therefore, we have examined the 
metal binding properties of PfMetAP-II so that a direct comparison of both type I and type II MetAP enzymes can 
be made under identical experimental conditions. 
To effectively study the PfMetAP-II enzyme by spectroscopic techniques, the gene that encodes PfMetAP-II was 
cloned and placed into a pET 27b(+) expression vector. After overexpression and purification, a 5-fold increase in 
enzyme production was observed, allowing 100 mg of purified PfMetAP-II to be obtained from 5 L fermentation 
growth. This increase in PfMetAP-II overproduction provides us the opportunity to perform a detailed 
structure−function analysis of type II MetAP's via detailed kinetic, spectroscopic, and X-ray crystallographic 
studies. The as-purified PfMetAP-II, to which no exogenous metal ions or EDTA was added, was shown to have 
∼1.2 equiv of zinc and ∼0.1 equiv of iron present by ICP-AES analysis. This enzyme had a specific activity of ∼5 
units/mg, a 60-fold decrease from the fully loaded Co(II) or Fe(II) enzymes. When two additional equivalents of 
Zn(II) were added to the as-purified PfMetAP-II, no activity could be detected. Similar results were reported 
for HsMetAP-II in which 0.78 ppm of Zn(II) ([HsMetAP-II]:[Zn(II)] = 1:1) was found after purification but the 
enzyme was essentially inactive (20). Moreover, EcMetAP-I is completely inactive in the presence of Zn(II). 
Interestingly, the as-purified PfMetAP-II contained ∼10% of the required amount of iron for activity (17). No 
cobalt could be detected within the 0.03 ppm detection limit for ICP-AES. Given the air sensitivity of the Fe(II) 
center in MetAP's, it is logical that the as-purified PfMetAP-II enzyme exhibited only ∼2% of the activity 
observed for Fe(II)-loaded PfMetAP-II under strict anaerobic conditions. These data are the first to directly 
indicate that MetAP's are Fe(II)-dependent enzymes. The low level of iron detected in the as-purified PfMetAP-II 
enzyme is likely the result of overwhelming the iron transport system during overexpression. The combination of 
these data with previously reported whole cell studies on EcMetAP-I (18) strongly suggests that the in vivo metal 
ion for all MetAP's is not Zn(II) or Co(II) but is, in fact, Fe(II). 
PfMetAP-II can be fully activated by both Co(II) or Fe(II) (Table 1). The kinetic parameters display similarities 
to EcMetAP-I and HsMetAP-II (17, 20). Moreover, the observed Km values for Fe(II)-loaded PfMetAP-II are almost 
always smaller than those for the Co(II)-loaded enzyme. The substrate binding affinity (Km) is largely affected by 
the amino acid in the P1‘ position as well as the length of the polypeptide used as the substrate. For the 
substrates MAS, MGMM, and MSSHRWDW, the Km values are in the millimolar range, but the Km value 
decreased for both Co(II)- and Fe(II)-loaded PfMetAP-II as the peptide chain length increased. For comparison, 
assayed in the presence of 0.5 mM Co(II), ScMetAP-I showed a Km value of 6.6 mM for the tetrapeptide MGMM 
while the Km value toward the octapeptide MSSHNTDT was found to be 0.019 mM (31). This difference in Km is 
likely because a longer peptide can interact with other amino acid residues in or near the active site. 
X-ray crystallographic studies on HsMetAP-II, PfMetAP-II, and EcMetAP-I have all shown that two Co(II) ions 
reside in a dinuclear active site with a M−M distance ranging from 2.9 to 3.1 Å (13−16). However, it has also 
been shown that one metal ion is loosely associated with EcMetAP-I, ScMetAP-I, and the human homologue of 
the rat initiation factor 2 associated protein (17, 26, 28). Recent EXAFS studies on EcMetAP-I revealed the lack of 
a dinuclear site at enzyme concentrations of 1 mM even in the presence of excess divalent metal ions (19). 
These data strongly suggest that, under physiological conditions, a dinuclear active site does not form in 
MetAP's. The observation that MetAP's are dinuclear metalloproteases is based solely on X-ray crystallographic 
studies in which at least a 10-fold excess of Co(II) was added to millimolar concentrations of enzyme during 
crystallization (13−16). The lack of a dinuclear center is also consistent with ICP-AES analyses of EcMetAP-I, 
which indicated that, upon the addition of divalent metal ions, only one is tightly bound per enzyme molecule 
(17). ICP-AES analyses of PfMetAP-II also revealed only one divalent metal ion tightly bound per enzyme 
molecule, under anaerobic conditions, similar to EcMetAP-I. 
Titration of apo-PfMetAP-II (8.3 μM) with either Co(II) or Fe(II) under anaerobic conditions revealed that both 
metal ions fully activate the enzyme after the addition of only 1 equiv (Figure 2; inset). Further additions of up to 
5 equiv of Co(II) or Fe(II) did not alter the enzymatic activity. Fits of these titration data provided dissociation 
constants (Kd) for the first metal binding site of 50 and 20 nM for Co(II)- and Fe(II)-loaded PfMetAP-II, 
respectively. Since only one metal ion is bound to the enzyme active site, these Kd values correspond to the 
microscopic binding constants for the binding of a single metal ion to PfMetAP-II. Kd values of 300 and 200 nM 
have been reported for Co(II)- and Fe(II)-loaded EcMetAP-I (17), respectively, which are similar in magnitude to 
those observed for PfMetAP-II. These Kd values are also similar to Kd values obtained for several other hydrolytic 
enzymes that contain carboxylate-rich active sites. For example, the Kd value for the first metal binding site of 
the aminopeptidase from A. proteolytica is 1 nM (29), the clostridial aminopeptidase exhibits a Kd value of 2 μM 
(30), the clostridial AMPP has a reported Kd value of 7 μM (30), and the β-lactamase from Bacillus cereus has a 
divalent metal ion Kd value of 620 nM (31). 
The addition of 8 equiv of divalent metal ions to PfMetAP-II up to 400 equiv, inhibited the enzymatic activity by 
∼30%. Similar results were observed for EcMetAP-I, ScMetAP-I, and HsMetAP-II in which the addition of excess 
divalent metal ions inhibited the enzymatic activity (17, 20, 26). These data suggest that the binding of a second 
metal ion to all MetAP's is inhibitory, which would imply that the second metal ion either has no catalytic role or 
is regulatory. Inhibition of catalytic activity by excess divalent metal ions has also been observed for other 
mononuclear metalloenzymes such as carboxypeptidase Taq when overexpressed in E. coli (32), bovine 
carboxypeptidase A (33, 34), and thermolysin (35). Inhibition of carboxypeptidase A was attributed to excess 
metal ion binding to an amino acid residue near the metallo active site that was involved in catalysis (33). In 
addition, the authors proposed that a bridging hydroxide, inserted between the two metal ions, forming a 
dinuclear site, was the result of the second metal ion binding event. This proposal was corroborated by X-ray 
crystallography where the structures of carboxypeptidase A as well as thermolysin in the presence of excess 
metal ion revealed two coordinated metal ions forming a (μ-hydroxo)dizinc(II) core with a Zn−Zn distance of 3.48 
and 3.2 Å, respectively (35−37). Therefore, the observation that the addition of excess metal ions to EcMetAP-
I, ScMetAP-I, HsMetAP-II, and PfMetAP-II inhibited enzymatic activity suggests that inhibition is likely due to the 
occupation of the second metal binding site, similar to carboxypeptidase A. 
To further examine the metal binding properties of PfMetAP-II, the electronic absorption spectra of Co(II)-
loaded PfMetAP-II (1 mM) were recorded. Upon the addition of 1 equiv of Co(II) under anaerobic conditions, 
three resolvable d−d transitions at 525, 562, and 590 nm (ε = 72, 110, and 93 M-1 cm-1, respectively) were 
observed. On the basis of ligand-field theory (25), these data indicate that the first Co(II) ion to bind to PfMetAP-
II resides in a pentacoordinate site, in agreement with X-ray crystallography (14). These data are also nearly 
identical to those previously reported for EcMetAP-I (17), further suggesting the similarity in the active sites of 
both type I and type II MetAP's. Upon the addition of 2 equiv of Co(II) the absorption spectrum does not change 
appreciably but the molar absorptivity continues to increase until more than 7 equiv of Co(II) have been added. 
These data suggest that the second Co(II) ion also resides in a pentacoordinate environment but that it is loosely 
bound to the enzyme. Fits of the two absorption maxima at 525 and 562 nm provided a Kd at pH 7.5 for the 
second metal binding site of 0.35 mM. Therefore, the ability of PfMetAP-II to bind one vs two divalent metal ions 
is very different (17.5 × 103 times), indicating that under physiological conditions the second metal binding site is 
unoccupied. On the basis of these data, we propose that PfMetAP-II functions as a mononuclear hydrolase in 
vivo similar to that of EcMetAP-I (17). However, Yang et al. (20) recently suggested that HsMetAP-II requires two 
Co(II) ions for full enzymatic activity to be achieved, based on the titration of Co(II) ions under aerobic conditions 
into a 100 nM HsMetAP-II sample with 1 equiv of tightly bound Zn(II). On the basis of simple equilibrium 
principles, as outlined in Scheme 1, and the assumption that the Kd value for the first metal binding site 
in HsMetAP-II is 50 nM, the value reported herein for PfMetAP-II, under the experimental conditions reported 
by Yang et al. (20), HsMetAP-II, would only have ∼0.5 equiv of Co(II) bound at a Co(II) concentration of 100 nM. 
This calculation assumes that HsMetAP-II is apo but, in fact, 1 equiv of Zn(II) was present which likely competes 
with Co(II) binding at the active site. Therefore, the low level of activity observed for HsMetAP-II in the presence 
of 1 equiv of Co(II) (100 nM) is quite reasonable as is the observed increase in activity in the presence of 100 
equiv of Co(II) (10 μM). At a Co(II) concentration of 10 μM, the total Co(II) concentration would now be at least 
10-fold greater than the equilibrium constant, providing an HsMetAP-II enzyme that has one Co(II) binding site 
>95% filled. Therefore, the data reported by Yang et al. (20) are completely consistent with HsMetAP-II 
functioning in vivo as a mononuclear metalloprotease, identical to EcMetAP-I and PfMetAP-II. 
Co(II) + 𝑃𝑃𝑓𝑓MetAp− II
k1
⇌
k.1
[Co(II)_(𝑃𝑃𝑓𝑓MetAP − II)] 
Co(II) + [Co(II)_(𝑃𝑃𝑓𝑓MetAP − II)]
k2
⇌
k.2
[Co(II)Co(II)(𝑃𝑃𝑓𝑓MetAP− II)] 
Scheme 1 
An important question in understanding the cleavage of N-terminal methionine residues from polypeptide 
chains by MetAP's is “what is the rate-limiting step in the catalytic reaction?” Since PfMetAP-II is stable at 75 °C 
for 1 h, PfMetAP-II provides the unique opportunity to determine the activation parameters of the ES⧧ complex 
over a wide temperature range. Construction of an Arrhenius plot from the temperature dependence 
of PfMetAP-II activity indicates that the rate-limiting step does not change as a function of temperature and is 
product release (22). The activation energy (Ea) for the activated ES⧧ complex is 13.3 and 19.4 kJ/mol for Co(II)- 
and Fe(II)-loaded PfMetAP-II, respectively. These data are approximately one-half the Ea reported for the 
aminopeptidase from A. proteolytica (36.5 kJ/mol) which has an activation energy similar to those of Pronase 
and both thermolysin and carboxypeptidase A (38−40). The enthalpy of activation calculated over the 
temperature range 25−85 °C is 11.0 and 17.0 kJ/mol for Co(II)- and Fe(II)-loaded PfMetAP-II, respectively, while 
the entropy of activation was found to be −119.7 and −99.7 J mol-1·K-1 for Co(II)- and Fe(II)-loaded PfMetAP-II, 
respectively, at 25 °C. The positive enthalpy is indicative of a conformation change upon substrate binding, likely 
due to the energy of bond formation and breaking during nucleophilic attack on the scissile carbonyl carbon of 
the substrate. On the other hand, the large negative entropy value suggests that some of the molecular motions 
are lost upon ES⧧ complex formation possibly due to hydrogen bond formation between catalytically important 
amino acids and the substrate. All of these factors contribute to the large positive free energy of activation. 
Interestingly, Fe(II)-loaded PfMetAP-II is 1.4 times more active than Co(II)-loaded PfMetAP-II at 85 °C. However, 
the Km values for both Co(II)- and Fe(II)-loaded PfMetAP-II are identical, within experimental error, indicating 
that Fe(II)-loaded PfMetAP-II is a much better catalyst at the optimum growth temperature of P. furiosus (85 °C). 
These data further suggest that Fe(II) is the physiologically relevant metal ion. 
In conclusion, the data presented herein provide new evidence that MetAP's are Fe(II) metalloproteases (Figure 
7) on the basis of the fact that the as-purified PfMetAP-II contains both iron and zinc; however, Zn(II) does not 
activate the enzyme, but Fe(II) provides a fully active enzyme, under anaerobic conditions. PfMetAP-II, 
like EcMetAP-I, is fully active in the presence of 1 equiv of Co(II) or Fe(II), and excess divalent metal ions inhibit 
enzymatic activity. Furthermore, electronic absorption spectra of [Co-(PfMetAP-II)] like [Co-(EcMetAP-I)] suggest 
that the first Co(II) binding site is five coordinate, consistent with X-ray crystallographic data. The only difference 
observed in divalent metal binding properties between type I and type II MetAP's is the magnitude of 
the Kd values for both metal binding sites. The Kd values observed for type II MetAP's are approximately 10 times 
smaller than those observed for type I enzymes. These data suggest that the 62 amino acid insert found in type 
II MetAP's alters the enzyme structure in such a way as to increase the enzyme's affinity for divalent metal ions. 
Combination of the data presented herein with divalent metal binding data previously reported for all MetAP's, 
including HsMetAP-II, suggests that type II MetAP's bind metal ions in exactly the same way as type I MetAP's. 
These data are not surprising since all MetAP active site ligands are strictly conserved and the active sites of the 
three crystallographically characterized MetAP's are completely superimposable. Therefore, all MetAP's likely 
function as mononuclear Fe(II) metalloproteases under physiological conditions. 
 
Figure 7 Proposed active site structure of Fe(II)-loaded MetAP's. The amino acid numbering is for EcMetAP-I with 
the amino acid numbers for PfMetAP-II in parentheses. 
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β-d-thiogalactoside; Hepes, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; Tris, 
tris(hydroxymethyl)aminomethane; SDS−PAGE, sodium dodecyl sulfate−polyacrylamide gel 
electrophoresis; HPLC, high-performance liquid chromatography; TFA, trifluoroacetic acid; ICP-AES, 
inductively coupled plasma atomic emission spectrometry; MAS, Met-Ala-Ser; MGMM, Met-Gly-Met-
Met; MSSHRWDW, Met-Ser-Ser-His-Arg-Trp-Asp-Trp; MP-p-NA, methionylprolyl-p-nitroanilide. 
 
